Big Sky Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2012
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics (D1)
Organizer(s) Paul W. Noble, Shelia M. Violette and Scott L. Friedman
March 30—April 4, 2012
Big Sky Resort • Big Sky, MT USA
Abstract Deadline: Nov 30, 2011
Late Abstract Deadline: Jan 5, 2012
Scholarship Deadline: Nov 30, 2011
Early Registration Deadline: Jan 30, 2012
Sponsored by Bayer USA Foundation, Celgene Corporation, GlaxoSmithKline UK, Hoffmann-La Roche, Inc. and Regulus Therapeutics Inc.
Summary of Meeting:
Fibrosis is a pathological process in which diseased tissue is replaced with excess extracellular matrix ultimately leading to organ scarring and failure, a final common pathway in many forms of chronic disease affecting multiple tissues. Currently, there are minimal and inadequate treatment options for fibrotic disease. There is an urgent need to understand the cellular, molecular and genetic basis of fibrosis in humans and develop animal models that replicate and illuminate this pathological process. There is also a need to identify prognostic markers of disease susceptibility, biomarkers of disease progression and improved technologies to monitor the effectiveness of new therapies. The goal of the Keystone Symposia meeting on Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics is to bring together researchers and clinicians in academia and industry to provide an integrated perspective of basic disease mechanisms, and to address the more pragmatic challenges associated with executing clinical trials and refining approaches to accelerate the clinical development of anti-fibrotic drugs.
View Scholarships/Awards
Fibrosis is a pathological process in which diseased tissue is replaced with excess extracellular matrix ultimately leading to organ scarring and failure, a final common pathway in many forms of chronic disease affecting multiple tissues. Currently, there are minimal and inadequate treatment options for fibrotic disease. There is an urgent need to understand the cellular, molecular and genetic basis of fibrosis in humans and develop animal models that replicate and illuminate this pathological process. There is also a need to identify prognostic markers of disease susceptibility, biomarkers of disease progression and improved technologies to monitor the effectiveness of new therapies. The goal of the Keystone Symposia meeting on Fibrosis: Translation of Basic Research to Human Disease and Novel Therapeutics is to bring together researchers and clinicians in academia and industry to provide an integrated perspective of basic disease mechanisms, and to address the more pragmatic challenges associated with executing clinical trials and refining approaches to accelerate the clinical development of anti-fibrotic drugs.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
FRIDAY, MARCH 30
SATURDAY, MARCH 31
SUNDAY, APRIL 1
MONDAY, APRIL 2
TUESDAY, APRIL 3
WEDNESDAY, APRIL 4
Conference Program Print | View meeting in 24 hr (international) time
FRIDAY, MARCH 30
7:15—8:30 PM
Welcome and Keynote Address
*
Paul W. Noble,
Cedars-Sinai Medical Center, USA
Eric N. Olson,
University of Texas Southwestern Medical Center, USA
MicroRNAs in Tissue Remodeling and Disease
MicroRNAs in Tissue Remodeling and Disease
8:00—11:15 AM
Epithelial Injury, Tissue Remodeling and Repair
Rachel C. Chambers,
University College London, UK
Coagulation Cascade, Tissue Injury and Repair in the Lung
Coagulation Cascade, Tissue Injury and Repair in the Lung
Victor J. Thannickal,
University of Alabama at Birmingham, USA
Targeting the Myofibroblast in Fibrotic Lung Disease
Targeting the Myofibroblast in Fibrotic Lung Disease
Harold A. Chapman,
University of California, San Francisco, USA
Epithelial Responses to Lung Injury: Role of the Extracellular Matrix
Epithelial Responses to Lung Injury: Role of the Extracellular Matrix
*
Dean Sheppard,
University of California, San Francisco, USA
Roles for alphav Integrins on Epithelial Cells and Myofibroblasts in Regulating Tissue Fibrosis
Roles for alphav Integrins on Epithelial Cells and Myofibroblasts in Regulating Tissue Fibrosis
Lynn M. Schnapp,
University of Wisconsin-Madison, USA
Short Talk: Role of Urokinase Plasminogen Activator Receptor Associated Protein (uPARAP) in Lung Injury and Repair
Short Talk: Role of Urokinase Plasminogen Activator Receptor Associated Protein (uPARAP) in Lung Injury and Repair
Vladimir V. Kalinichenko,
Cincinnati Children's Hospital Medical Center, USA
Short Talk: Foxm1 Transcription Factor Increases Epithelial-to-Mesenchymal Transition and is Required for Radiation-Induced Pulmonary Fibrosis
Short Talk: Foxm1 Transcription Factor Increases Epithelial-to-Mesenchymal Transition and is Required for Radiation-Induced Pulmonary Fibrosis
5:00—7:00 PM
Unfolded Protein Response and Endoplasmic Reticulum-Stress-Induced Injury
*
Gisli Jenkins,
University of Nottingham, UK
David Ron,
University of Cambridge, UK
Unfolded Protein Stress in the Endoplasmic Reticulum and the Extracellular Matrix
Unfolded Protein Stress in the Endoplasmic Reticulum and the Extracellular Matrix
Timothy S. Blackwell,
Vanderbilt University School of Medicine, USA
Dysfunctional Alveolar Epithelial Cells as a Result of Mutant Surfactant Protein C Expression: A Potential Link to Pathogenesis of IPF
Dysfunctional Alveolar Epithelial Cells as a Result of Mutant Surfactant Protein C Expression: A Potential Link to Pathogenesis of IPF
Gökhan S. Hotamisligil,
Harvard School of Public Health, USA
ER Stress, Chronic Inflammation, and Metabolic Disease
ER Stress, Chronic Inflammation, and Metabolic Disease
Natalie J. Torok,
University of California, Davis, USA
Short Talk: TIMP3/TACE Controls Inflammatory and Fibrogenic Activity in Non Alcoholic Steatohepatitis via NADPH Oxidase-Derived Reactive Oxidative Species
Short Talk: TIMP3/TACE Controls Inflammatory and Fibrogenic Activity in Non Alcoholic Steatohepatitis via NADPH Oxidase-Derived Reactive Oxidative Species
8:00—11:15 AM
Progenitor Cells and Cellular Plasticity in Fibrosis
Raghu Kalluri,
University of Texas MD Anderson Cancer Center, USA
Organ Fibrosis: Mechanism and Molecular Connection to Cancer
Organ Fibrosis: Mechanism and Molecular Connection to Cancer
Jeremy S. Duffield,
Vertex Pharmaceuticals, USA
Cell Fate Mapping and Pericytes in Kidney Injury and Fibrosis
Cell Fate Mapping and Pericytes in Kidney Injury and Fibrosis
*
Anna Mae Diehl,
Duke University, USA
Hedgehog, Progenitors and Epithelial Progenitors
Hedgehog, Progenitors and Epithelial Progenitors
David A. Brenner,
University of California, San Diego, USA
Fibrosis from EMT and Non-Resident Mesenchymal Cells - Fact or Fiction?
Fibrosis from EMT and Non-Resident Mesenchymal Cells - Fact or Fiction?
Jelena Mann,
Newcastle University, UK
Short Talk: Protective Adaptation to Liver Fibrosis in a Single Generation by Heritable Epigenetic Modifications
Short Talk: Protective Adaptation to Liver Fibrosis in a Single Generation by Heritable Epigenetic Modifications
Ivan Bertoncello,
University of Melbourne, Australia
Short Talk: Regulation of Endogenous Lung Epithelial Stem/Progenitor Cells by Lung Mesenchymal Cells and Cytokines
Short Talk: Regulation of Endogenous Lung Epithelial Stem/Progenitor Cells by Lung Mesenchymal Cells and Cytokines
2:00—4:30 PM
Workshop 1: Development of Novel Therapeutics in Fibrotic Disease
Steven R. Ledbetter,
Genzyme Corporation, USA
Neutralizing TGF-beta: A Promising Approach for the Treatment of Chronic Diseases
Neutralizing TGF-beta: A Promising Approach for the Treatment of Chronic Diseases
Eva van Rooij,
Hubrecht Institute, Netherlands
Novel Therapeutics in Cardiovascular Disease and Tissue Remodeling
Novel Therapeutics in Cardiovascular Disease and Tissue Remodeling
Mark L. Lupher, Jr.,
Muregen, LLC, USA
PRM-151, Recombinant Human Pentraxin-2: Preclinical and Clinical Progress
PRM-151, Recombinant Human Pentraxin-2: Preclinical and Clinical Progress
Victoria Smith,
Gilead Sciences, USA
Targeting Loxl2 in Fibrotic Disease
Targeting Loxl2 in Fibrotic Disease
Anne Minnich,
Sanofi Phamaceuticals, USA
SAR156597: An Innovative Bi-Specific IL-4/IL-13 Antibody as a Potential Treatment for Idiopathic Pulmonary Fibrosis
SAR156597: An Innovative Bi-Specific IL-4/IL-13 Antibody as a Potential Treatment for Idiopathic Pulmonary Fibrosis
5:00—7:00 PM
Tissue Remodeling in the Tumor Microenvironment
*
Sandra S. McAllister,
Brigham & Women's Hospital/Harvard Medical School, USA
The Systemic Environment as a Powerful Determinant of Stromal Desmoplasia and Tumor Malignancy
The Systemic Environment as a Powerful Determinant of Stromal Desmoplasia and Tumor Malignancy
Jeffrey W. Pollard,
Queen's Medical Research Institute, UK
Role of Macrophages and Tissue Remodeling in the Tumor Microenvironment
Role of Macrophages and Tissue Remodeling in the Tumor Microenvironment
Robert F. Schwabe,
Columbia University, USA
Promotion of Hepatocarcinogenesis by Activated Hepatic Stellate Cells
Promotion of Hepatocarcinogenesis by Activated Hepatic Stellate Cells
Janusz Franco-Barraza,
Fox Chase Cancer Center, USA
Short Talk: alphavbeta5/alpha5beta1-Integrin Crosstalk is Necessary to Maintain a Tumor-ECM Induced Myofibroblastic Phenotype
Short Talk: alphavbeta5/alpha5beta1-Integrin Crosstalk is Necessary to Maintain a Tumor-ECM Induced Myofibroblastic Phenotype
8:00—11:15 AM
Innate and Adaptive Mechanisms of Fibrosis
Paul W. Noble,
Cedars-Sinai Medical Center, USA
Innate Immune Regulation of Lung Fibrosis
Innate Immune Regulation of Lung Fibrosis
Andrew P. Fontenot,
University of Colorado Denver, USA
Immune Mechanisms of Lung Fibrosis in Granulomatous Inflammation
Immune Mechanisms of Lung Fibrosis in Granulomatous Inflammation
Tamiko R. Katsumoto,
Stanford University, USA
Short Talk: The Receptor-Type Protein Tyrosine Phosphatase CD148 Positively Regulates Pro-Fibrotic Signaling Pathways in Bleomycin-Induced Lung Fibrosis
Short Talk: The Receptor-Type Protein Tyrosine Phosphatase CD148 Positively Regulates Pro-Fibrotic Signaling Pathways in Bleomycin-Induced Lung Fibrosis
William C. Parks,
University of Washington, USA
MMPs Shape Fibrosis via Controlling Macrophage Activation
MMPs Shape Fibrosis via Controlling Macrophage Activation
Christian Stockmann,
University of Zurich, Switzerland
Short Talk: Aberrant Remodeling of the Lymphatic Vasculature during Pulmonary Fibrosis – The Lymphatic Drainage Capacity as a Determinating Factor of Fibroproliferative Changes in the Lung
Short Talk: Aberrant Remodeling of the Lymphatic Vasculature during Pulmonary Fibrosis – The Lymphatic Drainage Capacity as a Determinating Factor of Fibroproliferative Changes in the Lung
2:00—4:30 PM
Workshop 2: Modeling Injury and Fibrosis
*
Martin R. J. Kolb,
McMaster University, Canada
Pär Gerwins,
Uppsala University, Sweden
An in vivo Neovascularization Assay for Screening Regulators of Angiogenesis and Assessing their Effects on Pre-Existing Vessels
An in vivo Neovascularization Assay for Screening Regulators of Angiogenesis and Assessing their Effects on Pre-Existing Vessels
Emily Hamburg,
Case Western Reserve University, USA
Stabilized beta-Catenin Activity in Dermal Fibroblasts Leads to Skin Fibrosis
Stabilized beta-Catenin Activity in Dermal Fibroblasts Leads to Skin Fibrosis
Lukasz Stawski,
Boston University, USA
Angiotensin II Induces Skin Fibrosis: A Novel Mouse Model of Dermal Fibrosis
Angiotensin II Induces Skin Fibrosis: A Novel Mouse Model of Dermal Fibrosis
Tomoko Hayashida,
Northwestern University, USA
Distinct and Sequential Roles for PI3Ks and TGF-beta Mediating Glomerular Sclerosis in Mouse Adriamycin Nephropathy
Distinct and Sequential Roles for PI3Ks and TGF-beta Mediating Glomerular Sclerosis in Mouse Adriamycin Nephropathy
Matthew Frieman,
University of Maryland, USA
Contribution of Alternatively Activated Macrophages to a Pro-Fibrotic Response during SARS Coronavirus Infection
Contribution of Alternatively Activated Macrophages to a Pro-Fibrotic Response during SARS Coronavirus Infection
Reinout Stoop,
TNO, Netherlands
Combination of Deuterated Water Labeling and Transcriptomics Analysis Identifies Processes Contributing to Collagen Deposition during Pulmonary Fibrosis
Combination of Deuterated Water Labeling and Transcriptomics Analysis Identifies Processes Contributing to Collagen Deposition during Pulmonary Fibrosis
5:00—7:00 PM
Fibroblasts and Myofibroblasts
Sem H. Phan,
University of Michigan Medical School, USA
Regulation of Myofibroblast Differentiation
Regulation of Myofibroblast Differentiation
*
Rebecca G. Wells,
University of Pennsylvania, USA
Myofibroblasts in Liver Fibrosis
Myofibroblasts in Liver Fibrosis
John Varga,
Feinberg School of Medicine, USA
Impaired PPAR-gamma Signaling in Scleroderma: Therapeutic Target
Impaired PPAR-gamma Signaling in Scleroderma: Therapeutic Target
Claire Dugast-Darzacq,
Institut de Biologie de l' École Normale Supérieure (IBENS), France
Short Talk: Identification of Key Transcription Factors in the Regulation of Fibroblast to Myofibroblast Differentiation in an ex vivo Model of Chronic Wound
Short Talk: Identification of Key Transcription Factors in the Regulation of Fibroblast to Myofibroblast Differentiation in an ex vivo Model of Chronic Wound
8:00—11:15 AM
Biomarkers in Fibrotic Disease: Facilitating Clinical Development
*
Michael Gilman,
Arrakis Therapeutics, USA
Naftali Kaminski,
Yale University School of Medicine, USA
RNA, microRNA and Protein Biomarkers in Interstitial Lung Disease
RNA, microRNA and Protein Biomarkers in Interstitial Lung Disease
Shelia M. Violette,
Q32 Bio, USA
Developing a Biomarker Strategy to Support the Clinical Development of STX-100, an alphavbeta6 Antibody, in Fibrotic Disease
Developing a Biomarker Strategy to Support the Clinical Development of STX-100, an alphavbeta6 Antibody, in Fibrotic Disease
Robert Lafyatis,
University of Pittsburgh Medical Center, USA
Biomarkers as Predictors of Disease in Scleroderma
Biomarkers as Predictors of Disease in Scleroderma
Gabe Kwong,
Georgia Institute of Technology, USA
Nanoparticle-Based Urinary Biomarkers in Liver Disease
Nanoparticle-Based Urinary Biomarkers in Liver Disease
Kenn Holmbeck,
NIDCR, National Institutes of Health, USA
Short Talk: Connective Tissue Homeostasis is Dependent on Membrane-Type Matrix Metalloproteinase (MT-MMP) Activity for Resolution of Fibrosis
Short Talk: Connective Tissue Homeostasis is Dependent on Membrane-Type Matrix Metalloproteinase (MT-MMP) Activity for Resolution of Fibrosis
Peter Caravan,
Harvard Medical School, Massachusetts General Hospital, USA
Short Talk: Collagen-Targeted Molecular MR Imaging of Liver Fibrosis
Short Talk: Collagen-Targeted Molecular MR Imaging of Liver Fibrosis
5:00—7:00 PM
What's New in the Field: Clinical Developments in Fibrosis
*
Richard P. Marshall,
GlaxoSmithKline, UK
Williamson Z. Bradford,
Intermune, Inc., USA
IPF Drug Development: Trials, Tribulations, and New Opportunities
IPF Drug Development: Trials, Tribulations, and New Opportunities
Scott L. Friedman,
Icahn School of Medicine at Mount Sinai, USA
Prospects for Antifibrotics in Liver Disease
Prospects for Antifibrotics in Liver Disease
Timothy W. Schacker,
University of Minnesota, USA
Short Talk: Antifibrotic Therapy in SIV Infection Preserves CD4 T Cell Populations and Improves Immune Reconstitution With Antiretroviral Therapy
Short Talk: Antifibrotic Therapy in SIV Infection Preserves CD4 T Cell Populations and Improves Immune Reconstitution With Antiretroviral Therapy
Christopher L. Leptak,
Food and Drug Administration, USA
Biomarker Utility in Drug Development and Clinical Trials: An FDA Regulatory Perspective
Biomarker Utility in Drug Development and Clinical Trials: An FDA Regulatory Perspective
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
|
Celera |
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
